Rubric Capital Management LP Chinook Therapeutics, Inc. Transaction History

Rubric Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$18.63 - $27.35 $4.27 Million - $6.27 Million	-229,357 Reduced 24.16%	719,809 $18.9 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $4.84 Million - $7.23 Million	384,813 Added 68.19%	949,166 $16.6 Million
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $2.74 Million - $3.54 Million	238,490 Added 73.19%	564,353 $7.2 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $3.88 Million - $6.81 Million	325,863 New	325,863 $5.17 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rubric Capital Management LP with notifications on news.